To further verify whether DCLK1 promotes the malignant phenotype of CCA through stimulating the PI3K/AKT/mTOR pathway, we employed LY294002, a specific inhibitor of the PI3K/AKT/mTOR pathway, to evaluate the special impact of DCLK1 on CCA progression regulation. Here, DCLK1 is linked to cholangiocarcinoma.